Cargando…

Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease

Biomarkers have the potential to aid in the study of Alzheimer’s disease (AD); unfortunately, AD biomarker values often have a high degree of overlap between healthy and AD individuals. This study investigates the potential utility of a series of novel AD biomarkers, the sixty second (129)Xe retenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Hane, Francis T., Li, Tao, Plata, Jennifer-Anne, Hassan, Ayman, Granberg, Karl, Albert, Mitchell S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023430/
https://www.ncbi.nlm.nih.gov/pubmed/29882765
http://dx.doi.org/10.3390/diagnostics8020041
_version_ 1783335867098595328
author Hane, Francis T.
Li, Tao
Plata, Jennifer-Anne
Hassan, Ayman
Granberg, Karl
Albert, Mitchell S.
author_facet Hane, Francis T.
Li, Tao
Plata, Jennifer-Anne
Hassan, Ayman
Granberg, Karl
Albert, Mitchell S.
author_sort Hane, Francis T.
collection PubMed
description Biomarkers have the potential to aid in the study of Alzheimer’s disease (AD); unfortunately, AD biomarker values often have a high degree of overlap between healthy and AD individuals. This study investigates the potential utility of a series of novel AD biomarkers, the sixty second (129)Xe retention time, and the xenon washout parameter, based on the washout of hyperpolarized (129)Xe from the brain of AD participants following inhalation. The xenon washout parameter is influenced by cerebral perfusion, T1 relaxation of xenon, and the xenon partition coefficient, all factors influenced by AD. Participants with AD (n = 4) and healthy volunteers (n = 4) were imaged using hyperpolarized (129)Xe magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) to determine the amount of retained xenon in the brain. At 60 s after the breath hold, AD patients retained significantly higher amounts of (129)Xe compared to healthy controls. Data was fit to a pharmacokinetic model and the xenon washout parameter was extracted. Xenon washout in white and grey matter occurs at a slower rate in Alzheimer’s participants ((129)Xe half-life time of 42 s and 43 s, respectively) relative to controls (20 s and 16 s, respectively). Following larger scale clinical trials for validation, the xenon washout parameter has the potential to become a useful biomarker for the support of AD diagnosis.
format Online
Article
Text
id pubmed-6023430
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60234302018-07-13 Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease Hane, Francis T. Li, Tao Plata, Jennifer-Anne Hassan, Ayman Granberg, Karl Albert, Mitchell S. Diagnostics (Basel) Article Biomarkers have the potential to aid in the study of Alzheimer’s disease (AD); unfortunately, AD biomarker values often have a high degree of overlap between healthy and AD individuals. This study investigates the potential utility of a series of novel AD biomarkers, the sixty second (129)Xe retention time, and the xenon washout parameter, based on the washout of hyperpolarized (129)Xe from the brain of AD participants following inhalation. The xenon washout parameter is influenced by cerebral perfusion, T1 relaxation of xenon, and the xenon partition coefficient, all factors influenced by AD. Participants with AD (n = 4) and healthy volunteers (n = 4) were imaged using hyperpolarized (129)Xe magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) to determine the amount of retained xenon in the brain. At 60 s after the breath hold, AD patients retained significantly higher amounts of (129)Xe compared to healthy controls. Data was fit to a pharmacokinetic model and the xenon washout parameter was extracted. Xenon washout in white and grey matter occurs at a slower rate in Alzheimer’s participants ((129)Xe half-life time of 42 s and 43 s, respectively) relative to controls (20 s and 16 s, respectively). Following larger scale clinical trials for validation, the xenon washout parameter has the potential to become a useful biomarker for the support of AD diagnosis. MDPI 2018-06-06 /pmc/articles/PMC6023430/ /pubmed/29882765 http://dx.doi.org/10.3390/diagnostics8020041 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hane, Francis T.
Li, Tao
Plata, Jennifer-Anne
Hassan, Ayman
Granberg, Karl
Albert, Mitchell S.
Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease
title Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease
title_full Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease
title_fullStr Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease
title_full_unstemmed Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease
title_short Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease
title_sort inhaled xenon washout as a biomarker of alzheimer’s disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023430/
https://www.ncbi.nlm.nih.gov/pubmed/29882765
http://dx.doi.org/10.3390/diagnostics8020041
work_keys_str_mv AT hanefrancist inhaledxenonwashoutasabiomarkerofalzheimersdisease
AT litao inhaledxenonwashoutasabiomarkerofalzheimersdisease
AT platajenniferanne inhaledxenonwashoutasabiomarkerofalzheimersdisease
AT hassanayman inhaledxenonwashoutasabiomarkerofalzheimersdisease
AT granbergkarl inhaledxenonwashoutasabiomarkerofalzheimersdisease
AT albertmitchells inhaledxenonwashoutasabiomarkerofalzheimersdisease